BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 6596586)

  • 1. Total and free plasma neuroleptic levels in schizophrenic patients.
    Tang SW; Glaister J; Davidson L; Toth R; Jeffries JJ; Seeman P
    Psychiatry Res; 1984 Dec; 13(4):285-93. PubMed ID: 6596586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haloperidol. Plasma levels and prolactin response as predictors of clinical improvement in schizophrenia: chemical v radioreceptor plasma level assays.
    Smith RC; Baumgartner R; Misra CH; Mauldin M; Shvartsburd A; Ho BT; DeJohn C
    Arch Gen Psychiatry; 1984 Nov; 41(11):1044-9. PubMed ID: 6497566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radio receptor assay of serum neuroleptic levels in psychiatric patients.
    Krska J; Sampath G; Shah A; Soni SD
    Br J Psychiatry; 1986 Feb; 148():187-93. PubMed ID: 2870755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility.
    Santos JL; Ramos JA; Prieto P; Almoguera I; Vazquez C; Rubio ME; Cabranes JA
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(6):917-25. PubMed ID: 2813809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients.
    Tune LE; Creese I; DePaulo JR; Slavney PR; Snyder SH
    J Nerv Ment Dis; 1981 Jan; 169(1):60-3. PubMed ID: 6108981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of serum haloperidol levels to clinical response in schizophrenic patients.
    Magliozzi JR; Hollister LE; Arnold KV; Earle GM
    Am J Psychiatry; 1981 Mar; 138(3):365-7. PubMed ID: 7468835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low serum neuroleptic levels predict relapse in schizophrenic patients.
    Brown WA; Laughren T; Chisholm E; Williams BW
    Arch Gen Psychiatry; 1982 Sep; 39(9):998-1000. PubMed ID: 6126172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of rapid neuroleptic response in male patients with schizophrenia.
    Petrie EC; Faustman WO; Moses JA; Lombrozo L; Csernansky JG
    Psychiatry Res; 1990 Aug; 33(2):171-7. PubMed ID: 2243894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics.
    Gagné MA; Cormier H; Leblanc G; Lévesque D; Di Paolo T
    Can J Psychiatry; 1993 Oct; 38(8):534-40. PubMed ID: 7902199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine.
    Minami H; Nakahara T; Miyahara A; Nakane Y
    Psychiatry Clin Neurosci; 1997 Aug; 51(4):217-22. PubMed ID: 9316167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical state and serum neuroleptic levels measured by radioreceptor assay in schizophrenia.
    Tune LE; Creese I; Depaulo JR; Slavney PR; Coyle JT; Snyder SH
    Am J Psychiatry; 1980 Feb; 137(2):187-90. PubMed ID: 6101524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
    Balant-Gorgia AE; Eisele R; Balant L; Garrone G
    Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients.
    Lindenmayer JP; Smith D; Katz I
    J Clin Psychiatry; 1984 Mar; 45(3):117-9. PubMed ID: 6142035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
    Kuhs H; Folkerts H
    Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum haloperidol and neuroleptic receptor levels in chronic psychosis.
    Cannon DJ; McMillan DE; Newton JE; Fody EP; Metzer WS; Claybrook M; Couch L; Paige SR
    Ann Clin Lab Sci; 1988; 18(5):378-83. PubMed ID: 3178137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
    Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
    Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chlorpromazine levels and the outcome of treatment in schizophrenic patients.
    May PR; Van Putten T; Jenden DJ; Yale C; Dixon WJ
    Arch Gen Psychiatry; 1981 Feb; 38(2):202-7. PubMed ID: 7212947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia.
    Goldman RS; Tandon R; Liberzon I; Goodson J; Greden JF
    Psychopathology; 1991; 24(4):247-52. PubMed ID: 1754657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbation of schizophrenia--some preliminary findings.
    Greenberg JS; Brown WA; Laughren TP; Krantz J
    Psychopharmacol Bull; 1983; 19(1):74-6. PubMed ID: 6131470
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.